About Qualitek Labs
Incorporated in May’2018 in New Delhi, Qualitek Labs is a NABL-accredited laboratory company providing testing, inspection, homologation, certification and consultancy services. Its coverage includes automotive, defence, food and agriculture, pharma and healthcare, metals and minerals, environment and water. The company describes its network as 10 owned labs and 6 labs operating under a Public Private Partnership model, providing pan-India coverage.
Business
Services span transportation and technology, food and life sciences, healthcare and skincare, natural resources, and environment and sustainability. Testing work includes EV batteries, food and pharmaceutical products, minerals, electrical and electronic equipment, and defence equipment. The company also offers vehicle and component homologation and certification consultancy through government-recognized testing authorities.
- Service model: The company describes a mix of contract testing, project-based validation and longer-term compliance partnerships, supported by a cloud-based Laboratory Information Management System.
- FY25 milestones: Work included drinking-water testing for the Ministry of Jal Shakti, coal testing empanelment with the Ministry of Coal, a dedicated VOC testing lab in Noida and a partnership for export homologation.
Industry
The note identifies regulatory requirements, quality standards, international trade and consumer demand for quality products as drivers for the testing, inspection and certification market. It cites a global TIC market size of $31.76 Bn. in 2024, estimated at $33.95 Bn. in 2025, and projects $61.9 Bn. in 2033, with a 6.9% CAGR for 2025 – 2033. Management estimates the Indian TIC market at $7.62 Bn. in 2024 and $14 Bn. by 2033; after adjusting for government labs and MNCs, the report estimates an addressable market of INR 30,000 Cr. for Qualitek Labs.
Investment Rationale
- Broad testing portfolio: The company serves multiple industries and reports compliance with Indian and international standards, with services ranging from automotive and EV battery testing to food, pharmaceutical and mineral testing.
- Growth record: From FY23 to FY25, the report gives three-year CAGRs of 91.5% for revenue, 75.2% for EBITDA and 61.5% for PAT.
- New labs and operating leverage: The company added 9 labs in the last 18 months. The report says these labs have annual revenue potential of INR 120 Cr. over the next 2-3 years, compared with INR 8.9 Cr. of H1FY26 revenue from them.
- Management guidance: Management guidance is for 2x revenue every 2 years and ~30% EBITDA margins till the company achieves INR 500 Cr. of topline.
- Industry demand: The report links growth prospects to stricter quality requirements and regulatory activity, and estimates an addressable market of INR 30,000 Cr. for the company.
- Expansion plans: The stated priorities include lab process outsourcing, geographic expansion and new testing capabilities, including semiconductor and automotive, pharma, food and infrastructure labs.
Qualitek Labs Key Financials
| Particulars | FY24 | FY25 | FY26E | FY27E | FY28E |
|---|---|---|---|---|---|
| Sales (INR Cr.) | 29.2 | 70.2 | 110.0 | 160.0 | 230.0 |
| % Y-o-Y | 52.5% | 140.6% | 56.6% | 45.5% | 43.8% |
| EBITDA (INR Cr.) | 8.0 | 16.2 | 25.3 | 40.0 | 69.0 |
| PAT (INR Cr.) | 4.3 | 7.7 | 10.5 | 18.4 | 33.4 |
| EBITDA % | 27.6% | 23.1% | 23.0% | 25.0% | 30.0% |
| PAT % | 14.75 | 10.9% | 9.5% | 11.5% | 14.5% |
FY25 consolidated operating revenue was 70.2, EBITDA was 16.2 and PAT was 7.7. For H1-FY26, the historical financials table reports revenue of 54.2, EBITDA of 11.2 and PAT of 4.8. The report notes that established labs delivered EBITDA margins of 32%, while new labs incurred losses.
Valuation and Target Price
The valuation applies a target P/E range of 40.0x – 45.0x to FY27 PAT. The report presents an implied target price of INR 633 - 712 against a current market price of INR 335, and states potential upside of 89% to 113%. No formal Buy, Hold, Reduce or Sell recommendation is stated in the note.
- INR 335.0/-
- CMP
- INR 633 - 712
- Implied target price
- 89% to 113%
- Potential upside
Peer Comparison
The listed-peer table compares Qualitek Labs with Choksi Labs. It reports Qualitek Labs’ FY25 revenue at 70.2 and EBITDA margin at 23.1%, against Choksi Labs’ revenue of 42 and EBITDA margin of 27.0%. The table lists three-year revenue, EBITDA and PAT CAGRs of 91.5%, 75.2% and 61.5% for Qualitek Labs, compared with 10.1%, 4.9% and (31.2%) for Choksi Labs.
Management
- Antaryami Nayak: The CEO is a qualified CA and previously served as Regional Finance Director at Bureau Veritas - CPS, with earlier roles at Titan and Avery Dennison.
- Kamal Grover: The Executive Director leads sales and business development. His previous roles include positions at Avery Dennison and Bureau Veritas.
- Alok Kumar Agarwal: The Non-Executive Director has over 27 years of professional experience in finance and taxation.
- Mangesh Bhosale: The Director has over 26 years of leadership experience and a Master’s degree in Mechanical & Automation Engineering.
Key Risks
- Competition and customer onboarding: The TIC sector includes government labs, MNCs and smaller players. The report notes customer onboarding cycles can be long, including because some customers prefer MNC testing labels.
- Capital requirements and debt: Adding labs organically or through acquisitions requires continuing capex. The report cites debt of ~INR 72 Cr. as on Sep’25 and a Debt to Equity ratio of 0.51x.
- New labs have yet to break even: Nine new labs incurred an EBITDA loss of INR 3.3 Cr. in H1FY26. The report cites a minimum gestation period of 2-3 years for new labs to breakeven.
Our View
The thesis combines a diversified testing platform and strong reported growth with the prospect of newer labs contributing more as they mature. The key execution questions are whether these labs can reach breakeven and whether growth can be achieved while managing the capital needs. The report gives an implied target range of INR 633 - 712 and potential upside of 89% to 113%, but does not state a formal stock rating.